熱門資訊> 正文
BILI，EXAI和ENVB在市场前的输家中
2024-03-21 20:43
- Losers: Destination XL Group (DXLG) -16% after Q4 earnings release.
- Tourmaline Bio (TRML) -30%.
- Apyx Medical Corp (APYX) -17% after Q4 earnings release.
- Five Below (FIVE) -12% after Q4 earnings release.
- Designer Brands (DBI) -12% after Q4 earnings release.
- Academy Sports and Outdoors (ASO) -12% after Q4 earnings release.
- Paltalk (PALT) -11%.
- Exscientia plc (EXAI) -11% after FY earnings release.
- Treasure Global (TGL) -11%.
- Pyxis Oncology (PYXS) -11% reports financial results for fourth Quarter and full year 2023.
- InflaRx N.V. (IFRX) -11% reports FY results.
- Anghami (ANGH) -10%.
- Li Auto (LI) -9% after slashing Q1 delivery target
- LexinFintech Holdings Ltd. (LX) -8% after Q4 earnings release.
- Baozun (BZUN) -7% after Q4 earnings release.
- Accenture (ACN) -7% after Q2 earnings release.
- Bilibili (BILI) -6%.
- Danimer Scientific (DNMR) -6% looks to raise $15M in a direct offering.
- Enveric Biosciences (ENVB) -6%.
- TruGolf Holdings (TRUG) -6%.
- SCWorx Corp. (WORX) -5%.
More on Pre-market losers & stocks.
- Bilibili Stock Downgraded To Sell After Assessing Q4 Earnings
- Bilibili Inc. (BILI) Q4 2023 Earnings Call Transcript
- Bilibili Inc. 2023 Q4 - Results - Earnings Call Presentation
- Exscientia FY 2023 Earnings Preview
- Enveric gains on out-licensing deal of new chemical entities for joint disease treatments
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
